Mary McCormack
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mary McCormack has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan A. Ledermann
Department of Oncology, UCL Cancer Institute, University College London, London, UK
4 shared publications - Nicola MacDonald
University College London Hospital NHS Foundation Trust, Department of Gynaecological Oncology, London, UK
3 shared publications - Rebecca Kristeleit
Guy's and St Thomas' NHS Foundation Trust, London, England
3 shared publications Adeola Olaitan
UCL Cancer Institute and UCL Hospitals, London, United Kingdom (C.M., R.K., J.A.L.)
2 shared publicationsAllan Hackshaw
Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK
2 shared publicationsGemma Eminowicz
University College Hospital NHS Trust, London NW1 2BU, UK
2 shared publications
Latest Publications
- 22 August 2025
- Published by Elsevier in The Lancet
- Vol. 406 (10505) , 807
INTERLACE: not a new standard for cervical cancer chemoradiation – Authors' reply
- 22 August 2025
- Published by Elsevier in The Lancet
- Vol. 406 (10505) , 807
INTERLACE: not a new standard for cervical cancer chemoradiation – Authors' reply
- Open Access
Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London
Background: Ethnic and socioeconomic disparities in cancer outcomes are exacerbated by clinical trial underrepresentation. This study aims to identify inequalities in ethnicity and socioeconomic features among ovarian cancer clinical trial participants in two London cancer centres. Methods: All ovarian cancer patients treated between 2017 and 2022 were included. Patients participating in clinical trials were classified as the trial population (TP); the remainder were considered the non-trial population (NTP). Data on disease characteristics and sociodemographic features, including ethnicity and Indices of Multiple Deprivation (IMD) deciles, were accessed from electronic patient records. Results: Of the 892 patients, 212 (24%) were enrolled in trials: 87 in Phase II, 103 in Phase III, and 21 in prospective, non-investigational medicinal product trials. The TP were more likely to be of White ethnicity (72.6% vs. 57.5%; p < 0.001), younger (mean age 58 vs. 60; p = 0.003), living in less deprived areas (most deprived tercile: 21.2% vs. 34.0%; p = 0.004), and English-speaking (95.8% vs. 90.9%; p = 0.041). In the multivariate analysis, White ethnicity (p < 0.0001), age (p = 0.003), IMD decile (p = 0.007), and interpreter requirement (p = 0.037) were independent predictors of trial participation. Conclusions: Ethnic and socioeconomic inequalities affect trial participation, potentially worsening health disparities in ovarian cancer patients. Strategies to overcome trial recruitment barriers for underserved groups are needed to improve the equity of care.
Open AccessEthnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London
Background: Ethnic and socioeconomic disparities in cancer outcomes are exacerbated by clinical trial underrepresentation. This study aims to identify inequalities in ethnicity and socioeconomic features among ovarian cancer clinical trial participants in two London cancer centres. Methods: All ovarian cancer patients treated between 2017 and 2022 were included. Patients participating in clinical trials were classified as the trial population (TP); the remainder were considered the non-trial population (NTP). Data on disease characteristics and sociodemographic features, including ethnicity and Indices of Multiple Deprivation (IMD) deciles, were accessed from electronic patient records. Results: Of the 892 patients, 212 (24%) were enrolled in trials: 87 in Phase II, 103 in Phase III, and 21 in prospective, non-investigational medicinal product trials. The TP were more likely to be of White ethnicity (72.6% vs. 57.5%; p < 0.001), younger (mean age 58 vs. 60; p = 0.003), living in less deprived areas (most deprived tercile: 21.2% vs. 34.0%; p = 0.004), and English-speaking (95.8% vs. 90.9%; p = 0.041). In the multivariate analysis, White ethnicity (p < 0.0001), age (p = 0.003), IMD decile (p = 0.007), and interpreter requirement (p = 0.037) were independent predictors of trial participation. Conclusions: Ethnic and socioeconomic inequalities affect trial participation, potentially worsening health disparities in ovarian cancer patients. Strategies to overcome trial recruitment barriers for underserved groups are needed to improve the equity of care.
- Top Cited PapersOpen Access
- 14 October 2024
- Published by Elsevier in The Lancet
- Vol. 404 (10462) , 1525-1535
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial
- 14 October 2024
- Published by Elsevier in The Lancet
- Vol. 404 (10462) , 1525-1535
Top Cited PapersOpen AccessInduction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial
- Open Access
- 31 May 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (11) , e448-e455
Current Management Practices for Endometrial Cancer (EC) in the UK: A National Healthcare Professional Survey (KNOW-EC)
- 31 May 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (11) , e448-e455
Open AccessCurrent Management Practices for Endometrial Cancer (EC) in the UK: A National Healthcare Professional Survey (KNOW-EC)
- Open Access
- 23 March 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 186, 172-184
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice
- 23 March 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 186, 172-184
Open AccessHealth-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice
- Open Access
- 31 March 2022
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 106, 102385
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials
- 31 March 2022
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 106, 102385
Open AccessIntegration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials
- Open Access
- 1 May 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (5) , 775-778
The Cervical Cancer Research Network (Gynecologic Cancer InterGroup) roadmap to expand research in low- and middle-income countries
Cervical cancer is a global health problem which disproportionally affects women in low- and middle- income countries. The World Health Organization recently launched its global strategy to eliminate this disease in the next two decades. For those women diagnosed today with cervical cancer better strategies are needed to improve outcome and reduce treatment-related morbidity. Clinical trials are critical to shaping future treatment, and much has been achieved already. However, such opportunities are limited in low resource settings, and the Cervical Cancer Research Network is dedicated to expanding access to new technologies in surgery, radiation, and medical oncology. In this article we review the status of the trials portfolio and outline future objectives, including the launch of a number of research grants for aspiring or established researchers in low- and middle-income settings
- 1 May 2021
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 31 (5) , 775-778
Open AccessThe Cervical Cancer Research Network (Gynecologic Cancer InterGroup) roadmap to expand research in low- and middle-income countries
Cervical cancer is a global health problem which disproportionally affects women in low- and middle- income countries. The World Health Organization recently launched its global strategy to eliminate this disease in the next two decades. For those women diagnosed today with cervical cancer better strategies are needed to improve outcome and reduce treatment-related morbidity. Clinical trials are critical to shaping future treatment, and much has been achieved already. However, such opportunities are limited in low resource settings, and the Cervical Cancer Research Network is dedicated to expanding access to new technologies in surgery, radiation, and medical oncology. In this article we review the status of the trials portfolio and outline future objectives, including the launch of a number of research grants for aspiring or established researchers in low- and middle-income settings
- 1 August 2018
- Published by Elsevier in Clinical Oncology
- Vol. 30 (8) , 504-506
Radiation Therapy in Ovarian Cancer: An Overview and Future Directions
- 1 August 2018
- Published by Elsevier in Clinical Oncology
- Vol. 30 (8) , 504-506
Radiation Therapy in Ovarian Cancer: An Overview and Future Directions
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , 5581
Clear cell ovarian cancer (CCOC): 115 patient (pt) series showing access to experimental therapy may improve response rates in recurrent disease.
5581Background: 10 year survival for ovarian cancer (OC) in the UK has improved from 18% (1971) to a predicted survival of 35% (2011). Historical data show pts with advanced CCOC have worse survival compared to other histological subtypes of epithelial OC. We sought to determine treatment type and outcome of CCOC pts at 2 UK gynaecological cancer centres. Methods: Medical records of pts with CCOC treated between 2002 and 2017 were reviewed. Data collected comprised pt and tumour characteristics, treatment and outcome. Results: 115 pts, median age 56 (29-86) years (y) with CCOC were identified: stage (S) I (62), II (16), III (23), IV (8) and unknown (6). 91 pts had pure CCOC and 24 had mixed histopathology: endometrioid (83%), serous (12%), other (5%). Endometriosis co-existed in 43 (37%) pts; 34 pure CCOC, 8 mixed endometrioid. BRCA mutations were present in 4/19 tested and MMR loss in 2/8 tested. 21/23 pts with a thromboembolic event and 9/10 pts with hypercalcaemia (2.72-3.63mmol/L) had advanced or recu...
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , 5581
Clear cell ovarian cancer (CCOC): 115 patient (pt) series showing access to experimental therapy may improve response rates in recurrent disease.
5581Background: 10 year survival for ovarian cancer (OC) in the UK has improved from 18% (1971) to a predicted survival of 35% (2011). Historical data show pts with advanced CCOC have worse survival compared to other histological subtypes of epithelial OC. We sought to determine treatment type and outcome of CCOC pts at 2 UK gynaecological cancer centres. Methods: Medical records of pts with CCOC treated between 2002 and 2017 were reviewed. Data collected comprised pt and tumour characteristics, treatment and outcome. Results: 115 pts, median age 56 (29-86) years (y) with CCOC were identified: stage (S) I (62), II (16), III (23), IV (8) and unknown (6). 91 pts had pure CCOC and 24 had mixed histopathology: endometrioid (83%), serous (12%), other (5%). Endometriosis co-existed in 43 (37%) pts; 34 pure CCOC, 8 mixed endometrioid. BRCA mutations were present in 4/19 tested and MMR loss in 2/8 tested. 21/23 pts with a thromboembolic event and 9/10 pts with hypercalcaemia (2.72-3.63mmol/L) had advanced or recu...
- Open Access
- 1 May 2017
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 72 (5) , 279-280
Outcome of Patients With Advanced Ovarian Cancer Who Do Not Undergo Debulking Surgery: A Single Institution Retrospective Review
(ed from Gynecol Oncol 2017;144:57–60) The cornerstone of ovarian cancer (OC) treatment is debulking surgery to remove all residual disease. Recommended treatment for advanced OC (FIGO [International Federation of Gynecology and Obstetrics] III–IV) is optimal primary debulking surgery followed by platinum-based chemotherapy.
- 1 May 2017
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 72 (5) , 279-280
Open AccessOutcome of Patients With Advanced Ovarian Cancer Who Do Not Undergo Debulking Surgery: A Single Institution Retrospective Review
(ed from Gynecol Oncol 2017;144:57–60) The cornerstone of ovarian cancer (OC) treatment is debulking surgery to remove all residual disease. Recommended treatment for advanced OC (FIGO [International Federation of Gynecology and Obstetrics] III–IV) is optimal primary debulking surgery followed by platinum-based chemotherapy.